These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 1373485

  • 1. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 5. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 6. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 9. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG, Ma QL, Liu GF.
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun 28; 27(3):277-8. PubMed ID: 12575316
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG, Preston DF, Baxter KG, Dusing RW, Spicer JA.
    Semin Oncol; 1993 Jun 28; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [Abstract] [Full Text] [Related]

  • 15. Bone pain palliation with strontium-89 in cancer patients with bone metastases.
    Giammarile F, Mognetti T, Resche I.
    Q J Nucl Med; 2001 Mar 28; 45(1):78-83. PubMed ID: 11456379
    [Abstract] [Full Text] [Related]

  • 16. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy.
    Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, Ferraironi A, Rea S, Maini CL.
    Clin Ter; 1998 Mar 28; 149(921):43-7. PubMed ID: 9621488
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
    De Ruysscher D, Spaas P, Specenier P.
    Acta Urol Belg; 1996 Sep 28; 64(3):13-9. PubMed ID: 8946776
    [Abstract] [Full Text] [Related]

  • 20. External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.
    Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S.
    Oncol Rep; 2003 Sep 28; 10(2):399-404. PubMed ID: 12579279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.